Company Encyclopedia
View More
name
Palisade Bio
PALI.US
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The company’s lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor that is in phase 1a/b clinical trial for the treatment of ulcerative colitis, as well as under phase 1a clinical trial for the treatment of fibrostenotic crohn’s disease. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd.
1.935 T
PALI.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    DigitalBridge Group, Eightco Holdings, Palisade Bio And Other Big Stocks Moving Higher On Monday

    U.S. stocks were down, but several companies saw significant gains on Monday. DigitalBridge Group Inc (NYSE:DBRG) shares rose 9.9% to $15.30 after announcing its acquisition by SoftBank Group for $4 billion. Eightco Holdings Inc (NASDAQ:ORBS) jumped 29.1% due to a $125 million share buyback program. Palisade Bio Inc (NASDAQ:PALI) surged 18.6% after receiving an Overweight rating from Piper Sandler with a $25 price target. Other notable gainers included Regencell Bioscience Holdings Ltd (16.3%), Praxis Precision Medicines Inc (13%), and Autolus Therapeutics PLC (7.8%).

    benzinga_article·
    US
    PALI
    +16.05%
    US
    DBRG
    +9.63%
    benzinga_article·
    US
    PALI
    +16.05%
    US
    DBRG
    +9.63%

    U.S. RESEARCH ROUNDUP-Expedia Group, Hasbro, Palisade Bio

    Wall Street analysts have updated their ratings and price targets for several U.S. companies. Expedia Group's target price is raised to $340 from $300 by Argus Research. Hasbro's target is increased to $95 from $90 by Jefferies. Palisade Bio receives an overweight rating and a new target price of $25 from Piper Sandler. Praxis Precision Medicines sees its target raised to $843 from $507 by BTIG, while Vail Resorts' target is cut to $234 from $237 by Truist Securities. Amicus Therapeutics and BP also saw target price adjustments.

    Reuters·
    US
    EXPE
    -0.52%
    US
    HAS
    +0.01%
    US
    PALI
    +16.05%
    Reuters·
    US
    EXPE
    -0.52%
    US
    HAS
    +0.01%
    US
    PALI
    +16.05%

    Palisade Bio Strengthens Clinical Leadership Team With Appointment Of James Izanec

    Dec 2 (Reuters) - Palisade Bio Inc:* PALISADE BIO STRENGTHENS CLINICAL LEADERSHIP TEAM WITH APPOINTMENT OF JAMES IZANEC, MD, AGAF AS VICE PRESIDENT, CLINICAL DEVELOPMENT Source text: Further company coverage:

    Reuters·
    US
    PALI
    +16.05%
    Reuters·
    US
    PALI
    +16.05%

    Palisade Bio to Present at the Piper Sandler 37th Annual Healthcare Conference

    Live webcast fireside chat on Thursday, December 4th at 10:30 AM ET ...

    GlobeNewswire·
    US
    PALI
    +16.05%
    GlobeNewswire·
    US
    PALI
    +16.05%

    Palisade Bio | 10-Q: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    PALI
    +16.05%
    LB filings·
    US
    PALI
    +16.05%
    © 2025 Longbridge｜Disclaimer